New patient treatment centre at The Christie NHS Foundation Trust

Share :
Published: 25 Nov 2010
Views: 6209
Rating:
Save
Helen Ferns - The Christie NHS Foundation Trust, Manchester, UK

Helen Ferns speaks about the new patient treatment centre opening as part of the Christie NHS Foundation Trust in Manchester. This unit will be the largest early clinical trials unit in the world, the largest chemotherapy facility in the UK (increasing treatments from 30,000 to 38,000 a year) and will also contain The Christie Clinic, a new private patients unit run in collaboration with Healthcare America to increase income for NHS services. Ms Ferns explains how the new facility will benefit patients, facilitate drug development, talks about the capacity to offer personalised therapies and discussed the imaging technologies that are available at the centre. There is a high degree of cooperation between the research and chemotherapy teams at the new centre; this is expected to increase the level of staff expertise and consequently improve the quality of care for patients.

Related Videos

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India

Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India
WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India ( Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India )
23 Oct 2024

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India

Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India
Alternative livelihood training programme for rural women who are employed in the tobacco industry in India ( Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India )
23 Oct 2024

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini
ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )
18 Oct 2024

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation

Dr Rom Leidner - Providence Cancer Institute, Portland, USA
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation ( Dr Rom Leidner - Providence Cancer Institute, Portland, USA )
17 Oct 2024

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients

Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )
9 Oct 2024

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial

Prof Benjamin Besse - Gustave Roussy, Paris, France
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial ( Prof Benjamin Besse - Gustave Roussy, Paris, France )
1 Oct 2024

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients

Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia
Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients ( Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia )
1 Oct 2024

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )
26 Sep 2024